Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Jenscare (健世科技) IPO: Candidate for Shorts

Jenscare (宁波健世科技) Pre-IPO:  Massive Delays After Missing the Boat

Jenscare (宁波健世科技) Pre-IPO: Differentiated Heart Valve Portfolio

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Jenscare Scientific / Equity Capital Markets

<ul>
<li>Jenscare raised HKD 154.8m (USD 28m) from its global offering and will list on the Hong Kong Stock Exchange on Monday, October 10th.</li>
<li>In the previous note, we looked at the company's business lines of medical devices for structural heart disease. We are of the view that the company's valuation is unjustifiably rich.</li>
<li>In this note, we provide an update for the IPO before trading debut.</li>
</ul>


Jenscare raised HKD 154.8m (USD 28m) from its global offering and will list on the Hong Kong Stock Exchange on Monday, October 10th.
In the previous note, we looked at the company's business lines of medical devices for structural heart disease. We are of the view that the company's valuation is unjustifiably rich.
In this note, we provide an update for the IPO before trading debut.


Jenscare (健世科技) IPO Trading: Weak Demand and Share Concentration